Treatment with losartan, which inhibits the signaling of Ang II through AT1, while potentiating the effects mediated by AT2, would result in decreased endothelial cell migration and lower disruption of interendothelial cell junctions, in addition to anti-inflammatory systemic effects (Marchesi et al., 2008) and would align with the hypothesis of a beneficial effect of Ang II in malaria severity. The gene discussed is AGTR1; the disease is malaria.